Pikray for sarcoma – pro
On May 24, 2019, the Food and Drug Administration approved alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
This drug is supported by significant evidence in breast cancer, and there are only scattered reports on its use for any sarcoma, and none in myxoid liposarcoma that I could find.
https://www.oncnursingnews.com/view/expert-discusses-exciting-advancements-in-sarcoma-treatment, Accessed 7/29/2025
Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 Jul 1;2(7):570-576. doi: 10.1158/2767-9764.CRC-22-0028. PMID: 36923283; PMCID: PMC10010328.
NCCN Sarcoma 2025